September 24, 2013 -- Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013. Details of the event are:
Location:
FTI Consulting
Holborn Gate
26 Southampton Buildings
London, WC2A 1PB
10.45 Registration with refreshments
11.00 Introduction
David Evans, Scancell Non-Executive Chairman
11.05 Cancer immunotherapy
Prof Peter Stern, Head of the Immunology Group, Paterson Institute for Cancer Research, University of Manchester
11.20 Scancell corporate update
Dr Richard Goodfellow, Joint CEO of Scancell
11.30 SCIB1 trial update and introduction to Moditope™
Prof Lindy Durrant, Joint CEO of Scancell
11.45 Q&A
12.00 Interactive panel discussion
Led by Prof Karol Sikora, Dean of Medicine , University of Buckingham; Honorary Consultant Oncologist at Hammersmith Hospital
Panellists include:
Prof Lindy Durrant,
Prof Peter Stern,
Dr Steve Chan, Consultant Oncologist, City Hospital, Nottingham University
and Prof Christian Ottensmeier, Dept. of Experimental Medicine, University of Southampton
12.45 Buffet lunch
13.30 Close
For Further Information:
Dr Richard Goodfellow, Joint CEO
Professor Lindy Durrant, Joint CEO Scancell Holdings Plc
Scancell Holdings Plc + 44 (0) 20 7831 3113
Camilla Hume/Stephen Keys Cenkos Securities + 44 (0) 20 7397 8900
Mo Noonan/Eleanor Clarke FTI Consulting + 44 (0) 20 7831 3113
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
Eleanor Clarke
Team Assistant
Strategic Communications
F T I Consulting
+44(0) 203 077 0480 direct
Eleanor.Clarke@fticonsulting.com
Holborn Gate, 26 Southampton Buildings
London, WC2A 1PB
www.fticonsulting.com
Help employers find you! Check out all the jobs and post your resume.
